Sepracor ends Xopenex copromotion with Abbott
Executive Summary
Sepracor's copromotion deal with Abbott's Ross division for Xopenex (levalbuterol) will end on Dec. 31. Sepracor is moving its sales force in-house as it ramps up for the launch of its insomnia agent Estorra (eszopiclone). Sepracor will expand sales force to approximately 1,250 reps. Estorra has been "approvable" at the agency since Feb. 27 (1"The Pink Sheet" March 8, 2004, p. 34)...
You may also be interested in...
Sepracor Estorra Is “Approvable” For Insomnia; Launch Goal Is Mid-Year
Sepracor will resubmit its NDA for the insomnia agent Estorra in one to three months after receiving an "approvable" letter Feb. 27
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.